Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, Open-label, Randomized Controlled Trial Male and female adults with liver
cirrhosis due to chronic hepatitis B virus infection who have low-level viremia and are
beyond treatment indications by current guidelines.
To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events
(hepatocellular carcinoma, liver-related events and death, decompensated liver cirrhosis) in
cirrhotic chronic hepatitis B patients with low-level viremia beyond treatment indications by
current guidelines, compared with best supportive care
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
National Evidence-Based Healthcare Collaborating Agency